Metis Global Partners LLC grew its stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 3.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,829 shares of the medical instruments supplier’s stock after acquiring an additional 333 shares during the period. Metis Global Partners LLC’s holdings in Becton, Dickinson and Company were worth $2,611,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently modified their holdings of BDX. WR Wealth Planners LLC grew its position in shares of Becton, Dickinson and Company by 1.4% during the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after buying an additional 42 shares during the period. Clear Creek Financial Management LLC grew its position in shares of Becton, Dickinson and Company by 5.1% during the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after buying an additional 44 shares during the period. Sound Income Strategies LLC grew its position in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the period. Central Pacific Bank Trust Division grew its position in shares of Becton, Dickinson and Company by 22.5% during the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 45 shares during the period. Finally, Tompkins Financial Corp grew its holdings in Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the period. 86.97% of the stock is owned by institutional investors.
Becton, Dickinson and Company Stock Performance
Shares of BDX stock opened at $225.15 on Friday. The company’s fifty day simple moving average is $236.44 and its 200-day simple moving average is $235.05. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The firm has a market cap of $65.08 billion, a PE ratio of 37.90, a P/E/G ratio of 1.72 and a beta of 0.43. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $249.89.
Becton, Dickinson and Company Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be given a dividend of $1.04 per share. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a yield of 1.85%. The ex-dividend date of this dividend is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is 63.97%.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on BDX. Raymond James decreased their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Evercore ISI boosted their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price target for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $283.00.
Read Our Latest Stock Report on BDX
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Recommended Stories
- Five stocks we like better than Becton, Dickinson and Company
- Overbought Stocks Explained: Should You Trade Them?
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Top-Performing Non-Leveraged ETFs This Year
- How to Capture the Benefits of Dividend Increases
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.